A panelist discusses how contemporary therapeutic approaches enable successful management of atopic dermatitis through examination of real-world patient cases that demonstrate effective disease control strategies using the latest treatment options.
A panelist discusses how topical treatments for atopic dermatitis can be strategically selected and applied across the lifespan, with considerations for age-specific needs from infancy through adulthood.
A panelist discusses how effective coordination between primary care providers and dermatologists creates a complementary care model that optimizes atopic dermatitis management through shared decision-making, clear communication pathways, and defined roles for each specialty.
A panelist discusses how treatment selection for atopic dermatitis is influenced by multiple considerations including disease severity, patient age, affected body regions, comorbidities, previous treatment responses, and patient preferences.
A panelist discusses how topical JAK inhibitors and AhR agonists represent emerging therapeutic approaches for atopic dermatitis that target specific inflammatory pathways to provide effective symptom relief with distinct mechanisms of action.
A panelist discusses how topical PDE4 inhibitors provide an effective, non-steroidal treatment option for atopic dermatitis by reducing inflammation and improving symptoms with a favorable safety profile.
A panelist discusses how clinicians can select optimal topical treatments for atopic dermatitis by carefully weighing efficacy against potential side effects to create personalized management plans for patients.
A panelist discusses how primary care practitioners can implement efficient diagnostic protocols and treatment pathways to better manage atopic dermatitis patients within the constraints of busy clinical settings.
A panelist discusses how healthcare providers can effectively identify and manage atopic dermatitis flares across different age groups, highlighting the unique challenges and treatment approaches for both pediatric and adult populations.
Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.